AUSTIN, Texas, Sept. 8 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), today announced that initial results from a study conducted at the NMI Natural and Medical Sciences Institute at the University of Tubingen in Germany demonstrate that its MAGPIX® system provides more cost effective and efficient results than a conventional microtiter plate based ELISA method.
"These initial results demonstrate why MAGPIX could be a good choice for every research laboratory," said Dr. Thomas Joos, the head of the Biochemistry Department at the Natural and Medical Sciences Institute. "The system is a great choice for labs seeking one platform that allows the efficiency of multiplexing as well as the ability to run single tests, as needed. It can help labs save resources, increase efficiency and maximize results."
The NMI Natural and Medical Sciences Institute performed a comparative study between the recently launched MAGPIX system and a conventional ELISA method. The study utilized an assay for soluble tumor necrosis factor receptor II to compare the analytical methods using several parameters including optimal detection antibody concentration, dynamic range and assay sensitivity, sample measurement, intra- and inter-assay precision, parallelism, and dilution linearity. In addition to analytical performance, a time and motion analysis, and a cost comparison was performed.
The findings from this initial study demonstrate that MAGPIX provides accurate assay results at costs of as much as half of the microtiter plate ELISA method with equivalent sensitivity. While total